<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03012971</url>
  </required_header>
  <id_info>
    <org_study_id>DEXanalgesiaLT</org_study_id>
    <nct_id>NCT03012971</nct_id>
  </id_info>
  <brief_title>Dexmedetomidine Supplemented Analgesia and 3-Year Survival After Cancer Surgery</brief_title>
  <official_title>Impact of Dexmedetomidine Supplemented Analgesia on 3-Year Survival in Elderly Patients After Cancer Surgery: a Multicenter Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University First Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A majority of the elderly patients undergo surgery for malignant tumors. For these patients,
      postoperative tumor recurrence and metastasis are main factors that worsen long-term
      outcomes. The investigators hypothesize that dexmedetomidine supplemented analgesia in
      elderly patients after cancer surgery may help to maintain immune function and improve
      long-term outcomes, possibly by relieving stress and inflammatory response, improving
      analgesic efficacy and sleep quality, and reducing delirium incidence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A majority of the elderly patients undergo surgery for malignant tumors. For these patients,
      postoperative tumor recurrence and metastasis are main factors that worsen the quality of
      life and shorten the duration of survival. Perioperative immune function is a key element
      that influences postoperative tumor recurrence and metastasis; but it is subject to the
      impacts of many factors. Studies showed that elevated cortisol level and inflammation
      provoked by surgical stress result in suppression of immune function, whereas dexmedetomidine
      alleviates the elevated cortisol level and inhibit excessive inflammation; high-dose opioids
      inhibit the immune function and increase the invasiveness of tumor cells, whereas
      dexmedetomidine reduces the consumption of opioids during perioperative period; postoperative
      sleep disturbances also impair immune function, whereas dexmedetomidine improves sleep
      quality in patients after surgery; occurrence of postoperative delirium is associated with
      increased mortality, whereas dexmedetomidine reduces delirium incidence. The investigators
      hypothesize that dexmedetomidine supplemented analgesia in elderly patients after cancer
      surgery may improve the long-term outcomes, possibly by relieving stress and inflammatory
      response, improving analgesic efficacy and sleep quality, and reducing delirium incidence.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>3-year overall survival after surgery</measure>
    <time_frame>Up to 3 years after surgery</time_frame>
    <description>3-year overall survival after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival rates at different time-points after surgery</measure>
    <time_frame>At the end of the 1st, 2nd, and 3rd year after surgery</time_frame>
    <description>Survival rates at different time-points after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of recurrence-free survival after surgery</measure>
    <time_frame>Up to 3 years after surgery</time_frame>
    <description>Duration of recurrence-free survival after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function of survival patients at 3 years after surgery</measure>
    <time_frame>At the end of 3 years after surgery</time_frame>
    <description>Cognitive function was assessed with Telephone Interview for Cognitive Function-Modified (TICS-M)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life of survival patients at 3 years after surgery</measure>
    <time_frame>At the end of 3 years after surgery</time_frame>
    <description>Quality of life was assessed with World Health Organization Quality of Life-Bref (WHOQOL-BREF)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Elderly</condition>
  <condition>Surgery</condition>
  <condition>Analgesia</condition>
  <condition>Dexmedetomidine</condition>
  <condition>Long-term Outcome</condition>
  <arm_group>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dexmedetomidine supplemented morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains a mixture of morphine (0.5 mg/ml) and dexmedetomidine (1.25 ug/ml), with a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Morphine analgesia is provided for patients in this group in the form of patient-controlled intravenous analgesia. The formula contains morphine (0.5 mg/ml), with a total volume of 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine supplemented morphine analgesia</intervention_name>
    <description>Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.</description>
    <arm_group_label>Dexmedetomidine group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine analgesia</intervention_name>
    <description>Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;= 65 years, &lt; 90 years;

          -  Scheduled to undergo cancer surgery under general anesthesia with an expected duration
             of surgery &gt;=2 hours;

          -  The diagnosis is primary malignancy, without preoperative radio- or chemotherapy;

          -  Patient-controlled intravenous analgesia is planned for postoperative analgesia.

        Exclusion Criteria:

          -  Refuse to participate;

          -  Preoperative history of schizophrenia, epilepsy, parkinsonism or myasthenia gravis;

          -  Inability to communicate in the preoperative period because of coma, profound dementia
             or language barrier;

          -  Presence of preoperative sleep apnea (diagnosed with sleep apnea, or a STOP-Bang score
             &gt;= 3);

          -  Brain trauma or neurosurgery;

          -  Preoperative left ventricular ejection fraction &lt; 30%, sick sinus syndrome, severe
             sinus bradycardia (&lt; 50 beats per minute), or second-degree or above atrioventricular
             block without pacemaker;

          -  Severe hepatic dysfunction (Child-Pugh class C); Severe renal dysfunction (requirement
             of renal replacement therapy before surgery);

          -  ASA classification &gt;= IV or unlikely to survive for more than 24 hours after surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong-Xin Wang, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dong-Xin Wang, MD,PhD</last_name>
    <phone>861083572784</phone>
    <email>wangdongxin@hotmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xian Su, MD</last_name>
    <phone>861083572460</phone>
    <email>suxxx@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong-Xin Wang, MD, PhD</last_name>
      <phone>8610 83572784</phone>
      <email>wangdongxin@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Xian Su, MD</last_name>
      <phone>8610 83572460</phone>
      <email>suxxxx@126.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xian Su, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Dyer CB, Ashton CM, Teasdale TA. Postoperative delirium. A review of 80 primary data-collection studies. Arch Intern Med. 1995 Mar 13;155(5):461-5. Review.</citation>
    <PMID>7864702</PMID>
  </reference>
  <reference>
    <citation>McDaniel M, Brudney C. Postoperative delirium: etiology and management. Curr Opin Crit Care. 2012 Aug;18(4):372-6. doi: 10.1097/MCC.0b013e3283557211. Review.</citation>
    <PMID>22732435</PMID>
  </reference>
  <reference>
    <citation>Mu DL, Wang DX, Li LH, Shan GJ, Li J, Yu QJ, Shi CX. High serum cortisol level is associated with increased risk of delirium after coronary artery bypass graft surgery: a prospective cohort study. Crit Care. 2010;14(6):R238. doi: 10.1186/cc9393. Epub 2010 Dec 30.</citation>
    <PMID>21192800</PMID>
  </reference>
  <reference>
    <citation>Shi CM, Wang DX, Chen KS, Gu XE. Incidence and risk factors of delirium in critically ill patients after non-cardiac surgery. Chin Med J (Engl). 2010 Apr 20;123(8):993-9.</citation>
    <PMID>20497703</PMID>
  </reference>
  <reference>
    <citation>Lat I, McMillian W, Taylor S, Janzen JM, Papadopoulos S, Korth L, Ehtisham A, Nold J, Agarwal S, Azocar R, Burke P. The impact of delirium on clinical outcomes in mechanically ventilated surgical and trauma patients. Crit Care Med. 2009 Jun;37(6):1898-905. doi: 10.1097/CCM.0b013e31819ffe38.</citation>
    <PMID>19384221</PMID>
  </reference>
  <reference>
    <citation>Quinlan N, Rudolph JL. Postoperative delirium and functional decline after noncardiac surgery. J Am Geriatr Soc. 2011 Nov;59 Suppl 2:S301-4. doi: 10.1111/j.1532-5415.2011.03679.x.</citation>
    <PMID>22091577</PMID>
  </reference>
  <reference>
    <citation>Lescot T, Karvellas CJ, Chaudhury P, Tchervenkov J, Paraskevas S, Barkun J, Metrakos P, Goldberg P, Magder S. Postoperative delirium in the intensive care unit predicts worse outcomes in liver transplant recipients. Can J Gastroenterol. 2013 Apr;27(4):207-12.</citation>
    <PMID>23616958</PMID>
  </reference>
  <reference>
    <citation>Abelha FJ, Luís C, Veiga D, Parente D, Fernandes V, Santos P, Botelho M, Santos A, Santos C. Outcome and quality of life in patients with postoperative delirium during an ICU stay following major surgery. Crit Care. 2013 Oct 29;17(5):R257. doi: 10.1186/cc13084.</citation>
    <PMID>24168808</PMID>
  </reference>
  <reference>
    <citation>Pisani MA, Kong SY, Kasl SV, Murphy TE, Araujo KL, Van Ness PH. Days of delirium are associated with 1-year mortality in an older intensive care unit population. Am J Respir Crit Care Med. 2009 Dec 1;180(11):1092-7. doi: 10.1164/rccm.200904-0537OC. Epub 2009 Sep 10.</citation>
    <PMID>19745202</PMID>
  </reference>
  <reference>
    <citation>Bickel H, Gradinger R, Kochs E, Förstl H. High risk of cognitive and functional decline after postoperative delirium. A three-year prospective study. Dement Geriatr Cogn Disord. 2008;26(1):26-31. doi: 10.1159/000140804. Epub 2008 Jun 24.</citation>
    <PMID>18577850</PMID>
  </reference>
  <reference>
    <citation>Van Rompaey B, Schuurmans MJ, Shortridge-Baggett LM, Truijen S, Elseviers M, Bossaert L. Long term outcome after delirium in the intensive care unit. J Clin Nurs. 2009 Dec;18(23):3349-57. doi: 10.1111/j.1365-2702.2009.02933.x. Epub 2009 Sep 4.</citation>
    <PMID>19735334</PMID>
  </reference>
  <reference>
    <citation>Ouimet S, Kavanagh BP, Gottfried SB, Skrobik Y. Incidence, risk factors and consequences of ICU delirium. Intensive Care Med. 2007 Jan;33(1):66-73. Epub 2006 Nov 11.</citation>
    <PMID>17102966</PMID>
  </reference>
  <reference>
    <citation>Stuck A, Clark MJ, Connelly CD. Preventing intensive care unit delirium: a patient-centered approach to reducing sleep disruption. Dimens Crit Care Nurs. 2011 Nov-Dec;30(6):315-20. doi: 10.1097/DCC.0b013e31822fa97c.</citation>
    <PMID>21983504</PMID>
  </reference>
  <reference>
    <citation>Siddiqi N, Harrison JK, Clegg A, Teale EA, Young J, Taylor J, Simpkins SA. Interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2016 Mar 11;3:CD005563. doi: 10.1002/14651858.CD005563.pub3. Review.</citation>
    <PMID>26967259</PMID>
  </reference>
  <reference>
    <citation>Kosar CM, Tabloski PA, Travison TG, Jones RN, Schmitt EM, Puelle MR, Inloes JB, Saczynski JS, Marcantonio ER, Meagher D, Reid MC, Inouye SK. EFFECT OF PREOPERATIVE PAIN AND DEPRESSIVE SYMPTOMS ON THE DEVELOPMENT OF POSTOPERATIVE DELIRIUM. Lancet Psychiatry. 2014 Nov;1(6):431-436.</citation>
    <PMID>25642413</PMID>
  </reference>
  <reference>
    <citation>Halaszynski TM. Pain management in the elderly and cognitively impaired patient: the role of regional anesthesia and analgesia. Curr Opin Anaesthesiol. 2009 Oct;22(5):594-9. doi: 10.1097/ACO.0b013e32833020dc. Review.</citation>
    <PMID>19623056</PMID>
  </reference>
  <reference>
    <citation>Rudolph JL, Ramlawi B, Kuchel GA, McElhaney JE, Xie D, Sellke FW, Khabbaz K, Levkoff SE, Marcantonio ER. Chemokines are associated with delirium after cardiac surgery. J Gerontol A Biol Sci Med Sci. 2008 Feb;63(2):184-9.</citation>
    <PMID>18314455</PMID>
  </reference>
  <reference>
    <citation>Brummel NE, Girard TD. Preventing delirium in the intensive care unit. Crit Care Clin. 2013 Jan;29(1):51-65. doi: 10.1016/j.ccc.2012.10.007. Review.</citation>
    <PMID>23182527</PMID>
  </reference>
  <reference>
    <citation>de Rooij SE, van Munster BC, Korevaar JC, Levi M. Cytokines and acute phase response in delirium. J Psychosom Res. 2007 May;62(5):521-5.</citation>
    <PMID>17467406</PMID>
  </reference>
  <reference>
    <citation>Mo Y, Zimmermann AE. Role of dexmedetomidine for the prevention and treatment of delirium in intensive care unit patients. Ann Pharmacother. 2013 Jun;47(6):869-76. doi: 10.1345/aph.1AR708. Review.</citation>
    <PMID>23719785</PMID>
  </reference>
  <reference>
    <citation>Huupponen E, Maksimow A, Lapinlampi P, Särkelä M, Saastamoinen A, Snapir A, Scheinin H, Scheinin M, Meriläinen P, Himanen SL, Jääskeläinen S. Electroencephalogram spindle activity during dexmedetomidine sedation and physiological sleep. Acta Anaesthesiol Scand. 2008 Feb;52(2):289-94. Epub 2007 Nov 14.</citation>
    <PMID>18005372</PMID>
  </reference>
  <reference>
    <citation>Oto J, Yamamoto K, Koike S, Onodera M, Imanaka H, Nishimura M. Sleep quality of mechanically ventilated patients sedated with dexmedetomidine. Intensive Care Med. 2012 Dec;38(12):1982-9. doi: 10.1007/s00134-012-2685-y. Epub 2012 Sep 8.</citation>
    <PMID>22961436</PMID>
  </reference>
  <reference>
    <citation>Coull JT, Jones ME, Egan TD, Frith CD, Maze M. Attentional effects of noradrenaline vary with arousal level: selective activation of thalamic pulvinar in humans. Neuroimage. 2004 May;22(1):315-22.</citation>
    <PMID>15110021</PMID>
  </reference>
  <reference>
    <citation>Memiş D, Hekimoğlu S, Vatan I, Yandim T, Yüksel M, Süt N. Effects of midazolam and dexmedetomidine on inflammatory responses and gastric intramucosal pH to sepsis, in critically ill patients. Br J Anaesth. 2007 Apr;98(4):550-2.</citation>
    <PMID>17363413</PMID>
  </reference>
  <reference>
    <citation>Tasdogan M, Memis D, Sut N, Yuksel M. Results of a pilot study on the effects of propofol and dexmedetomidine on inflammatory responses and intraabdominal pressure in severe sepsis. J Clin Anesth. 2009 Sep;21(6):394-400. doi: 10.1016/j.jclinane.2008.10.010.</citation>
    <PMID>19833271</PMID>
  </reference>
  <reference>
    <citation>Stone LS, MacMillan LB, Kitto KF, Limbird LE, Wilcox GL. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J Neurosci. 1997 Sep 15;17(18):7157-65.</citation>
    <PMID>9278550</PMID>
  </reference>
  <reference>
    <citation>Szumita PM, Baroletti SA, Anger KE, Wechsler ME. Sedation and analgesia in the intensive care unit: evaluating the role of dexmedetomidine. Am J Health Syst Pharm. 2007 Jan 1;64(1):37-44. Review.</citation>
    <PMID>17189578</PMID>
  </reference>
  <reference>
    <citation>Arcangeli A, D'Alò C, Gaspari R. Dexmedetomidine use in general anaesthesia. Curr Drug Targets. 2009 Aug;10(8):687-95.</citation>
    <PMID>19702517</PMID>
  </reference>
  <reference>
    <citation>Taniguchi T, Kidani Y, Kanakura H, Takemoto Y, Yamamoto K. Effects of dexmedetomidine on mortality rate and inflammatory responses to endotoxin-induced shock in rats. Crit Care Med. 2004 Jun;32(6):1322-6.</citation>
    <PMID>15187514</PMID>
  </reference>
  <reference>
    <citation>Can M, Gul S, Bektas S, Hanci V, Acikgoz S. Effects of dexmedetomidine or methylprednisolone on inflammatory responses in spinal cord injury. Acta Anaesthesiol Scand. 2009 Sep;53(8):1068-72. doi: 10.1111/j.1399-6576.2009.02019.x. Epub 2009 Jun 10.</citation>
    <PMID>19519725</PMID>
  </reference>
  <reference>
    <citation>Ueki M, Kawasaki T, Habe K, Hamada K, Kawasaki C, Sata T. The effects of dexmedetomidine on inflammatory mediators after cardiopulmonary bypass. Anaesthesia. 2014 Jul;69(7):693-700. doi: 10.1111/anae.12636. Epub 2014 Apr 28.</citation>
    <PMID>24773263</PMID>
  </reference>
  <reference>
    <citation>Pandharipande PP, Pun BT, Herr DL, Maze M, Girard TD, Miller RR, Shintani AK, Thompson JL, Jackson JC, Deppen SA, Stiles RA, Dittus RS, Bernard GR, Ely EW. Effect of sedation with dexmedetomidine vs lorazepam on acute brain dysfunction in mechanically ventilated patients: the MENDS randomized controlled trial. JAMA. 2007 Dec 12;298(22):2644-53.</citation>
    <PMID>18073360</PMID>
  </reference>
  <reference>
    <citation>Riker RR, Shehabi Y, Bokesch PM, Ceraso D, Wisemandle W, Koura F, Whitten P, Margolis BD, Byrne DW, Ely EW, Rocha MG; SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group. Dexmedetomidine vs midazolam for sedation of critically ill patients: a randomized trial. JAMA. 2009 Feb 4;301(5):489-99. doi: 10.1001/jama.2009.56. Epub 2009 Feb 2.</citation>
    <PMID>19188334</PMID>
  </reference>
  <reference>
    <citation>Peng K, Liu HY, Wu SR, Cheng H, Ji FH. Effects of Combining Dexmedetomidine and Opioids for Postoperative Intravenous Patient-controlled Analgesia: A Systematic Review and Meta-analysis. Clin J Pain. 2015 Dec;31(12):1097-104. doi: 10.1097/AJP.0000000000000219. Review.</citation>
    <PMID>25654534</PMID>
  </reference>
  <reference>
    <citation>Su X, Meng ZT, Wu XH, Cui F, Li HL, Wang DX, Zhu X, Zhu SN, Maze M, Ma D. Dexmedetomidine for prevention of delirium in elderly patients after non-cardiac surgery: a randomised, double-blind, placebo-controlled trial. Lancet. 2016 Oct 15;388(10054):1893-1902. doi: 10.1016/S0140-6736(16)30580-3. Epub 2016 Aug 16.</citation>
    <PMID>27542303</PMID>
  </reference>
  <reference>
    <citation>Hofer SO, Molema G, Hermens RA, Wanebo HJ, Reichner JS, Hoekstra HJ. The effect of surgical wounding on tumour development. Eur J Surg Oncol. 1999 Jun;25(3):231-43. Review.</citation>
    <PMID>10336800</PMID>
  </reference>
  <reference>
    <citation>Nguyen DP, Li J, Tewari AK. Inflammation and prostate cancer: the role of interleukin 6 (IL-6). BJU Int. 2014 Jun;113(6):986-92. doi: 10.1111/bju.12452. Review.</citation>
    <PMID>24053309</PMID>
  </reference>
  <reference>
    <citation>Schrepf A, Thaker PH, Goodheart MJ, Bender D, Slavich GM, Dahmoush L, Penedo F, DeGeest K, Mendez L, Lubaroff DM, Cole SW, Sood AK, Lutgendorf SK. Diurnal cortisol and survival in epithelial ovarian cancer. Psychoneuroendocrinology. 2015 Mar;53:256-67. doi: 10.1016/j.psyneuen.2015.01.010. Epub 2015 Jan 20.</citation>
    <PMID>25647344</PMID>
  </reference>
  <reference>
    <citation>Bekker A, Haile M, Kline R, Didehvar S, Babu R, Martiniuk F, Urban M. The effect of intraoperative infusion of dexmedetomidine on the quality of recovery after major spinal surgery. J Neurosurg Anesthesiol. 2013 Jan;25(1):16-24. doi: 10.1097/ANA.0b013e31826318af.</citation>
    <PMID>22824921</PMID>
  </reference>
  <reference>
    <citation>Ma J, Zhang XL, Wang CY, Lin Z, Tao JR, Liu HC. Dexmedetomidine alleviates the spinal cord ischemia-reperfusion injury through blocking mast cell degranulation. Int J Clin Exp Med. 2015 Sep 15;8(9):14741-9. eCollection 2015.</citation>
    <PMID>26628956</PMID>
  </reference>
  <reference>
    <citation>Roy S, Ninkovic J, Banerjee S, Charboneau RG, Das S, Dutta R, Kirchner VA, Koodie L, Ma J, Meng J, Barke RA. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J Neuroimmune Pharmacol. 2011 Dec;6(4):442-65. doi: 10.1007/s11481-011-9292-5. Epub 2011 Jul 26. Review.</citation>
    <PMID>21789507</PMID>
  </reference>
  <reference>
    <citation>Vassou D, Notas G, Hatzoglou A, Castanas E, Kampa M. Opioids increase bladder cancer cell migration via bradykinin B2 receptors. Int J Oncol. 2011 Sep;39(3):697-707. doi: 10.3892/ijo.2011.1063. Epub 2011 Jun 3.</citation>
    <PMID>21643624</PMID>
  </reference>
  <reference>
    <citation>Fujioka N, Nguyen J, Chen C, Li Y, Pasrija T, Niehans G, Johnson KN, Gupta V, Kratzke RA, Gupta K. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer. Anesth Analg. 2011 Dec;113(6):1353-64. doi: 10.1213/ANE.0b013e318232b35a. Epub 2011 Oct 14.</citation>
    <PMID>22003224</PMID>
  </reference>
  <reference>
    <citation>Friese RS. Sleep and recovery from critical illness and injury: a review of theory, current practice, and future directions. Crit Care Med. 2008 Mar;36(3):697-705. doi: 10.1097/CCM.0B013E3181643F29. Review.</citation>
    <PMID>18176314</PMID>
  </reference>
  <reference>
    <citation>Alexopoulou C, Kondili E, Diamantaki E, Psarologakis C, Kokkini S, Bolaki M, Georgopoulos D. Effects of dexmedetomidine on sleep quality in critically ill patients: a pilot study. Anesthesiology. 2014 Oct;121(4):801-7. doi: 10.1097/ALN.0000000000000361.</citation>
    <PMID>24988068</PMID>
  </reference>
  <reference>
    <citation>Skevington SM, McCrate FM. Expecting a good quality of life in health: assessing people with diverse diseases and conditions using the WHOQOL-BREF. Health Expect. 2012 Mar;15(1):49-62. doi: 10.1111/j.1369-7625.2010.00650.x. Epub 2011 Jan 31.</citation>
    <PMID>21281412</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2016</study_first_submitted>
  <study_first_submitted_qc>January 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2017</study_first_posted>
  <last_update_submitted>February 22, 2018</last_update_submitted>
  <last_update_submitted_qc>February 22, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University First Hospital</investigator_affiliation>
    <investigator_full_name>Dong-Xin Wang</investigator_full_name>
    <investigator_title>Professor and Chairman, Department of Anesthesiology and Critical Care Medicine</investigator_title>
  </responsible_party>
  <keyword>Elderly</keyword>
  <keyword>Surgery</keyword>
  <keyword>Analgesia</keyword>
  <keyword>Dexmedetomidine</keyword>
  <keyword>Long-term outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

